Infectious complications, whether associated or not with GVHD and its treatment, are a constant concern after allo-SCT. Viral infections are of particular concern because of difficulty in diagnosis, variable clinical presentation and propensity to disseminate owing to the immunological status of grafted patients.
We report a case of severe pleuro-pericarditis associated with Parvovirus B19 infection in an allografted patient.
A 40-year-old Caucasian man was diagnosed in April 2001 with chronic myeloid leukemia, in chronic phase. The Sokal score was low and the patient was treated with a-IFN and hydroxyurea, without hematological response after 6 months. Imatinib therapy was started and a hematological complete response was achieved after 1 month. Unfortunately, 4 months later, acute myeloid transformation was evident (marrow blasts 51%) and he received a classical 3 þ 7 induction chemotherapy for AML, which resulted in a second chronic phase.
In June 2002, an allo-SCT from a HLA-identical sibling was performed. The conditioning regimen was myeloablative, combining BU 4 mg/kg p.o. in divided doses daily for 4 days (total dose 16 mg/kg), melphalan (140 mg/m 2 ) and antithymocyte globulin (5 mg/kg). GVHD prophylaxis consisted of CyA and 'short-course' MTX. Peripheral stem cells were infused without any manipulation (CD34 þ cells: 7.3 Â 10 6 /kg). The immediate post-graft period was uneventful and molecular CR was documented between days þ 100 and þ 150. The patient developed extensive chronic GVHD (cutaneous and hepatic) at day þ 143, which was treated with CyA, mycophenolate mofetil and steroids. After an initial regression, a flare was diagnosed 15 months later (February 2004), which was treated with low-dose TLI (1.5 Gy) and by continuing the same immunosuppressive drugs. GVHD was considered to be in CR and immunosuppression was withdrawn in October 2007.
In May 2009, the patient was admitted to the Internal Medicine ward with fever and thoracic pain. Neither articular pain nor anemia was associated. A diagnosis of pleuro-pericarditis was made on the basis of radiological findings and broad-spectrum antibiotics were started. After 1 week, the hemodynamic status worsened on account of compressive pericardial effusion, and the patient was transferred to the cardiologic intensive care unit to perform pleural and pericardial drainage. Cytological findings were non-specific and microbiological cultures for bacteria and fungi were negative. PCR tests for different viruses were performed (see below). The patient was then transferred to the transplantation unit. At this time, the patient presented with dyspnea while under oxygen supplementation, with fever and thoracic pain. Computed tomography scan confirmed pleural and pericardial effusion. Blood cell count showed normochromic normocytic anemia (7.7 g/L), and a normal WBC and plt count. Renal function and hepatic profile were normal. Reticulocyte count was 81 000/L. Hemolysis tests were negative. BM evaluation showed an erythroid and megakaryocytic megaloblastosis, without blasts, and PCR for bcr/abl transcript was negative. In the meantime, qualitative real-time PCR on pericardial and pleural effusions yielded positive results for Parvovirus B19. PCR was also positive on the serum specimen. Other viruses tested by PCR in effusion specimens were negative. The patient was treated with polyvalent Igs (Ig total dose 2 g/kg, 500 mg/kg per day for 4 days), resulting in rapid apyrexia and partial reduction of pain. He was discharged after a few days on high-dose aspirin (3 g/day). Three months later (September 2009), the patient was in good clinical status (PS 100%), with no radiological signs of pleural or pericardial effusion.
Parvovirus B19 is a single-stranded DNA virus, which is largely distributed in the population (60-90% of adults are seropositive). 1 The virus is transmitted by respiratory droplets. Erythroid progenitors are the natural cell target in humans, 2 and are infected via the globoside (called also erythrocyte P Ag). Other cells, such as endothelial and myocardial cells, can also be infected. Parvovirus B19 is the etiological agent of several diseases such as Fifth disease and arthropathy, which are linked to precipitation of immune complexes. In patients with accelerated erythropoiesis because of chronic erythroid destruction, viral infection can produce transient aplastic crisis owing to progenitor suppression. In the immunosuppressed population, the impossibility of mounting an effective anticorpal response can be responsible for chronic viral persistence with pure red-cell aplasia. Furthermore, Parvovirus B19 has been associated with many complications after solid organ and allo-SCT. 3 Recently, Eid et al. 4 reported on 98 patients who received a graft (allo-SCT 24%), with Parvovirus B19 infection. The hallmark of the infection is chronic anemia (98% of patients), with leucopenia and thrombocytopenia in almost one-third of the cases. Interestingly, Parvovirus B19 was associated with diseases localized to different organs, such as myocarditis, pneumonitis, hepatitis, glomerulopathy and graft loss. Parvovirus-related mortality was 3%. In this comprehensive review of literature, no case of pleuro-pericarditis was retrieved.
In our patient, the causal relationship between pleuropericarditis and Parvovirus B19 infection can be questioned because of the risk of false-positive results due to the persistence of virus in normal tissue for several months after infection. 5 However, treatment with high-dose Ig was associated with a rapid clinical improvement (apyrexia), suggesting an effective clearance of virus. At the time of admission to the transplant unit, the patient was anemic and was transfused because of dyspnea. The relationship between anemia and Parvovirus B19 is doubtful because marrow examination showed erythroid megaloblastosis without typical giant normoblasts and the reticulocyte count was normal.
Finally, this case showed that Parvovirus B19 can be responsible for a rare clinical manifestation in allografted patients and that Ig treatment is effective.
